6-Methylsulfinyl hexyl isothiocyanate (6-MSITC)
FIGURE 1: Psychlomin™
also known as 6-MSITC
6-Methylsulfinyl hexyl isothiocyanate or 6-MSITC is a compound within the isothiocyanate group of organosulfur compounds. 6-MITC is obtained from cruciferous vegetables, chiefly wasabi. Like other isothiocyanates, it is produced when the enzyme memyrosinase transforms the associated glucosinolate into 6-MITC upon cell injury.
In a 2023 study of healthy older adults aged 60 years and over, the group taking one tablet (0.8 mg of 6-MSITC) every day for 12 weeks showed a significant improvement in working and episodic memory performances. https://pubmed.ncbi.nlm.nih.gov/37960261/
Figure 2
A summary of 6-MSITC biological activities (↓ decrease).
6-(Methylsulfinyl)hexyl isothiocyanate(6-MSITC) isolated from Wasabia japonica, also know as Eutrema japonicum, is a promising candidate for the treatment of breast cancer, colorectal and stomach cancer, metabolic syndrome, heart diseases, diabetes, and obesity due to its anti-inflammatory and antioxidant properties.
Also, its neuroprotective properties, improving cognitive function and protecting dopaminergic neurons, make it an excellent candidate for treating neurodegenerative diseases like dementia, Alzheimer's, and Parkinson's disease.
6-MSITC acts on many signaling pathways, such as PPAR, AMPK, PI3K/AKT/mTOR, Nrf2/Keap1-ARE, ERK1/2-ELK1/CHOP/DR5, and MAPK.
However, despite the very promising results of in vitro and in vivo animal studies and a few human studies, the molecule has not yet been thoroughly tested in the human population. Nonetheless, wasabi should be classified as a "superfood" for the primary and secondary prevention of human diseases. This article reviews the current state-of-the-art research on 6-MSITC and its potential clinical uses, discussing in detail the signaling pathways activated by the molecule and their interactions.
Keywords: AMPK; ERK; MAPK; Nrf; PPAR; Parkinson’s disease; breast cancer; chronic fatigue syndrome; colorectal-stomach cancer; mTOR.
NUTRITIONAL SUPPLEMENTS AND VITAMINS ARE MORE POPULAR THAN EVER. DO THEY WORK?
Dietary supplements — vitamins, minerals, botanicals and probiotics — are more popular than ever. More than three-quarters of Americans take at least one, according to the Food and Drug Administration.
Are any of them worth it?
The research is mixed. Some vitamins, including multivitamins, have been shown to be beneficial in large, randomized clinical trials. Others have been shown to potentially cause harm. Many lie somewhere in between.
As many as 100,000 different supplement products are sold in stores and online in the U.S., the FDA estimates. They range from multivitamins to herbs to concoctions that promise weight loss, including some that may be toxic or falsely claim to improve brain function.
Up to 4 in 10 people could develop dementia after 55. What you can do to lower your risk
WASHINGTON (AP) — About a million Americans a year are expected to develop dementia by 2060, roughly double today’s toll, researchers reported on January 13 2025.
That estimate is based on a new study that found a higher lifetime risk than previously thought: After age 55, people have up to a 4 in 10 chance of eventually developing dementia -- if they live long enough.
It’s a sobering number but there are steps people can take to reduce that risk, such as controlling high blood pressure and other bad-for-the-brain health problems. And it’s not too late to try even in middle age.
“All of our research suggests what you do in midlife really matters,” said Dr. Josef Coresh of NYU Langone Health, who coauthored the study in the journal Nature Medicine.
https://apnews.com/article/dementia-alzheimers-aging-brain-health-82b74dd1834b6387284164da655eaad8
Dementia risk may be twice as high as Americans live longer, study finds
The risk of developing dementia may be much higher than previously thought, a study published Monday [13 January 2025] in the journal Nature Medicine has found.
Older studies estimated that about 14% of men and 23% of women would develop dementia in their lifetimes. The new study puts that estimate higher, at around 42% for both men and women.
“I think this is going to be a very important study, and I think it is going to change the way we look at dementia,” said Dr. Ted Huey, director of the memory and aging program at Butler Hospital in Rhode Island, who wasn’t involved with the research.
More than anything, the increase in both risk and the number of people living with dementia — which the researchers estimated will double by 2060 — is the result of people living longer than previous generations, said study leader Dr. Josef Coresh, director of the Optimal Aging Institute at the NYU Grossman School of Medicine.
LIFETIME RISK AND PROJECTED BURDEN OF DEMENTIA
"The lifetime risk of dementia after age 55 years was 42%..."
"The number of US adults who will develop dementia each year was projected to increase from approximately 514,000 in 2020 to approximately 1 million in 2060."
*These statements have not been evaluated by the U.S. Food and Drug Administration (FDA). This product is not intended to diagnose, treat, cure, or prevent disease.
